Critical Reviews in Oncology Hematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Supporting Supportive Care in Cancer: The ethical importance of promoting a holistic conception of quality of life
Advances in anticancer therapies and increasing attention towards patient quality of life make Supportive Care in Cancer (SCC) a key aspect of excellence in oncological care. SCC promotes a holistic conception of quality of life encompassing clinical, ethical/existential, and spiritual dimensions. Despite the calls of international oncology societies empirical evidence shows that SCC has not yet been implemented. More efforts are needed given the clinical and ethical value of SCC not only for patients, but also for clinicians and hospitals. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 10, 2018 Category: Cancer & Oncology Authors: D. Carrieri, F.A. Peccatori, G. Boniolo Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 7, 2018 Category: Cancer & Oncology Source Type: research

Critical appraisal of oncological safety of stent as bridge to surgery in left-sided obstructing colon cancer; a systematic review and meta-analysis
Traditionally, acute malignant colonic obstruction has been managed with emergency surgery (ES), either consisting of acute resection or decompressing stoma construction. Resection in the emergency setting might be associated with a substantial risk of mortality and morbidity rates, especially in patients with high operative risk (Tanis et al., 2015; Dohmoto, 1991; Vitale et al., 2006). This resulted in the search for alternative treatment approaches. In 1991, Dohmoto first proposed the placement of a self-expandable metallic stent (SEMS) to relief colonic obstruction (Saida et al., 1996). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 3, 2018 Category: Cancer & Oncology Authors: Femke J. Amelung, Thijs A. Burghgraef, Pieter J. Tanis, Jeanin E. van Hooft, Frank ter Borg, Peter D. Siersema, Willem A. Bemelman, Esther C.J. Consten Source Type: research

The Era of PARP inhibitors in Ovarian Cancer: “Class Action” or not? A Systematic Review and Meta-Analysis
Among epithelial ovarian cancer (EOC) patients, women with genetic predisposition show an early onset of disease. Rare high penetrant mutations in BRCA1 and BRCA2 genes greatly increase lifetime risk and account for the majority of hereditary cases, 10% –15% of all cases. These women have a 40-60% lifetime risk of EOC (44% in BRCA1 families and 27% in BRCA2 families, respectively) (Mavaddat et al., 2012; Xu et al., 2017). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 3, 2018 Category: Cancer & Oncology Authors: Nicoletta Staropoli, Domenico Ciliberto, Teresa Del Giudice, Eleonora Iuliano, Maria Cuc è, Francesco Grillone, Angela Salvino, Vito Aldo Barbieri, Antonio Russo, Pierfrancesco Tassone, Pierosandro Tagliaferri Source Type: research

Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature
Stereotactic body radiotherapy (SBRT) is characterized by the delivery of high doses of ionizing radiation in few fractions. It is highly effective in achieving local control, and, due to the high biological effective dose administered, it seems to overcome the radioresistance of renal cell carcinoma (RCC). Thus, SBRT could constitute a treatment option for the management of localized RCC in patients who are not surgical candidates. In this paper, we report an overview about data from the current evidence about SBRT in patients affected by localized RCC. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 28, 2018 Category: Cancer & Oncology Authors: G. Francolini, B. Detti, G. Ingrosso, I. Desideri, C. Becherini, G. Carta, D. Pezzulla, G. Caramia, L. Dominici, V. Maragna, M.A. Teriaca, M. Bottero, L. Livi Source Type: research

Revisiting the Dynamic Cancer Stem Cell Model: Importance of Tumour Edges
The lack of an effective treatment against cancer is not only due to its huge heterogeneity, but also to the fact that we don ’t have an answer to the question on how cancer originates. Among the proposed models to explain the development of cancer, the hierarchical model has been widely accepted. Nevertheless, this model fails to explain several experimental observations such as the cancer stem cells (CSCs) location ins ide a tumour or the differences between primary and metastatic tumours. Moreover, increasing evidence shows that the CSC phenotype is not a rigid state. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 28, 2018 Category: Cancer & Oncology Authors: Pablo Hern ández-Camarero, Gema Jiménez, Elena López-Ruiz, Shivan Barungi, Juan Antonio Marchal, Macarena Perán Source Type: research

c-MET as a Potential Target Therapy Toward Personalized Therapy in Some Pediatric Tumors: An Overview
Although pediatric tumors represent less than 1% of all new cancer diagnoses, they still rank the second in the list of disease-related morbidity and mortality in children in the US. Combining biomarker-driven targeted therapy with individualized genomic analysis is the principle of precision medicine trials. The cellular –mesenchymal-epithelial transition (c-MET) factor receptor signaling pathway plays an important role in many physiological functions including embryological development. It, tightly, regulates changes in cell growth and survival, it also defines the general pattern of invasive growth during normal devel...
Source: Critical Reviews in Oncology Hematology - August 28, 2018 Category: Cancer & Oncology Authors: Wafaa M. Rashed Source Type: research

Can we avoid the toxicity of chemotherapy in elderly cancer patients?
Despite the fact that approximately 50% of patients with cancer are ≥70 years old (Siegel et al., 2016), cancer treatment in the elderly continues to represent a therapeutic challenge. Elderly patients form a very heterogeneous group in relation to their health condition, degree of dependence, comorbidities, performance status, physical reserve and geriatric situa tion, for which therapeutic decisions must be adopted in an individualized manner. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 28, 2018 Category: Cancer & Oncology Authors: Jaime Feliu, Victoria Heredia-Soto, Regina Giron és, Beatriz Jiménez-Munarri, Juana Saldaña, Carmen Guillén-Ponce, MJ Molina-Garrido Source Type: research

Duration of first-line treatment for metastatic colorectal cancer: translating the available evidence into general recommendations for routine practice
Over the last two decades the number of front-line regimens for metastatic colorectal cancer has progressively increased. Nevertheless, there is still no consensus on the optimal duration of treatment or the role of de-escalated/maintenance strategies after induction chemotherapy. In this article we provide an overview of the studies that addressed the duration of first-line systemic treatment with cytotoxic agents plus or minus targeted therapies highlighting caveats and limitations of the same. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 27, 2018 Category: Cancer & Oncology Authors: Federica Morano, Francesco Sclafani Source Type: research

Criteria for Eligibility to Cisplatin in the Curative Treatment of Head and Neck Cancer: Consensus Opinion from a Panel of Experts
Squamous-cell carcinoma of the head and neck (SCCHN) is an important problem in Brazil, where epidemiological and socioeconomic features often create barriers to the implementation of combined modalities with curative potential. Cisplatin improves the efficacy of radiotherapy in the adjuvant treatment of localized SCCHN and in the definitive therapy of locally advanced disease. However, the addition of high-dose cisplatin to radiotherapy increases treatment toxicity and is not always warranted. A panel of experts convened in Sao Paulo, Brazil, for discussions and recommendations regarding the use of high-dose cisplatin in ...
Source: Critical Reviews in Oncology Hematology - August 27, 2018 Category: Cancer & Oncology Authors: Gilberto de Castro, Gustavo V. Alves, Ana F. Castro, Aline L.F. Chaves, Pedro De Marchi, Thiago B. de Oliveira, Fernando L. Dias, Rodrigo S.C. Guindalini, Ulisses R. Nicolau, Andrey Soares, Paulo A.R. Mora Source Type: research

The role of pdgf-b/pdgfr-beta axis in the normal development and carcinogenesis of the breast
PDGFs/PDGFRs axis is documented as an important tumor-promoting agent and potential therapeutic target for several human carcinomas, including breast cancer. However, little is known about the role played by the PDGF family members in the normal development of the breast tissue, breast carcinogenesis and tumor-microenvironment dynamics Despite its potent pro-lymphangiogenic effects, PDGF-B/PDGFR-beta axis remains controversial and incompletely elucidated in the field of breast cancer, with emphasis to its differential implications in breast cancer molecular subtypes. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 27, 2018 Category: Cancer & Oncology Authors: Adriana-Andreea Jitariu, Marius Raica, Anca Maria C împean, Silviu Cristian Suciu Source Type: research

The effects of Mitochondria-associated long noncoding RNAs in cancer mitochondria: new players in an old arena
LncRNAs, as new players in the old battle against cancer, are significant components of gene regulatory networks. Mitochondria-associated lncRNAs have newly been discovered to work in concert with transcription factors and epigenetic regulators to modulate mitochondrial gene expression and mitochondrial function. Many mitochondria-associated lncRNAs regulate mitochondrial biosynthesis, bioenergetics, apoptosis and possibly govern the cross-talk of mitochondria with nuclei. The complexity of mitochondria-associated lncRNAs is now just starting to envisage. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 27, 2018 Category: Cancer & Oncology Authors: Yijing Zhao, Lemeng Sun, Rachel R. Wang, Ji-Fan Hu, Jiuwei Cui Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 8, 2018 Category: Cancer & Oncology Source Type: research

A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin
Metastatic renal cell carcinoma (mRCC) occurs in 25-30% of patients at diagnosis and develops in 40% after surgical treatment in localized stages (Choueiri and Motzer, 2017). Brain metastases (BM) are not a rare finding in mRCC as the 5-year cumulative incidence of BM RCC reaches 9.8% (Schouten et al., 2002). Other retrospective series report similar incidence of BM from RCC reaching 7 to 13% % (Ernest Marshall et al., 1990; Seaman et al., 1995; Ljungberg and Rasmuson, 1999; Shuch et al., 2008; Sun et al., 2018). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 7, 2018 Category: Cancer & Oncology Authors: Joseph Kattan, Elie El Rassy, Tarek Assi, Ziad Bakouny, Nicholas Pavlidis Source Type: research

Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis
SF3B1 gene mutations are the most frequent mutations found in myelodysplastic syndromes (MDS), and the prognostic implication of these mutations remains controversial. We conducted a meta-analysis of studies assessing the prognostic impact and clinical feature of SF3B1 mutations in MDS patients. The overall hazard ratio for overall survival (OS) was 0.90 (95% confidence interval 0.60-1.35, P  = 0.61) in MDS patients with SF3B1 mutations compared to those without. Lower leukemia-free survival was associated with SF3B1 mutations. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 3, 2018 Category: Cancer & Oncology Authors: Yaqiong Tang, Miao Miao, Shiyu Han, Jiaqian Qi, Hong Wang, Changgeng Ruan, Depei Wu, Yue Han Source Type: research